Physician profile
Michael J Streitmann
NPI 1386624450
$2,955.84
in general payments reported to CMS, 2019-2025
22 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $513 · 2021: $862 · 2022: $73.53 · 2023: $71.51 · 2024: $21.14 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,131.24 | 2019-2021 | |
| Allergan, INC. | $419.60 | 2019-2022 | |
| Galderma Laboratories, L.P. | $209.08 | 2020-2025 | |
| Revance Therapeutics, INC. | $186.69 | 2024-2025 | Daxi, Daxxify |
| Acelrx Pharmaceuticals, INC. | $170.42 | 2020 | |
| Lilly USA, LLC | $139.20 | 2025 | Ebglyss, Taltz |
| Genzyme Corporation | $114.63 | 2025 | |
| Mentor Worldwide LLC | $94.67 | 2021-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Regeneron Healthcare Solutions, INC. | $65.46 | 2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $61.93 | 2025 | Tremfya |
| Abbvie INC. | $58.50 | 2025 | |
| Incyte Corporation | $41.40 | 2025 | Opzelura |
| Heron Therapeutics, INC. | $41.34 | 2023 | Zynrelef |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.84 | 2025 | Cabtreo |
| Sun Pharmaceutical Industries INC. | $36.74 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.17 | 2023 | Seglentis |
| Leo Pharma INC. | $28.21 | 2025 | Adbry |
| Apyx Medical Corporation | $22.61 | 2019 | |
| Amgen INC. | $18.01 | 2025 | Otezla |
| Integra Lifesciences Corporation | $17.55 | 2021 | |
| Smith+Nephew, INC. | $15.33 | 2020 | |
| Botanix Sb INC | $14.22 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Streitmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.